Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines

The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). 77 cell lines displayed YM155 IC50s in the range of clinical YM155 concentrations. ABCB1 was an important determinant of YM155 resistance. The activity of the ABCB1 inhibitor zosuquidar ranged from being similar to that of the structurally different ABCB1 inhibitor verapamil to being 65-fold higher. ABCB1 sequence variations may be responsible for this, suggesting that the design of variant-specific ABCB1 inhibitors may be possible. Further, we showed that ABCC1 confers YM155 resistance. Previously, p53 depletion had resulted in decreased YM155 sensitivity. However, TP53-mutant cells were not generally less sensitive to YM155 than TP53 wild-type cells in this study. Finally, YM155 cross-resistance profiles differed between cells adapted to drugs as similar as cisplatin and carboplatin. In conclusion, the large cell line panel was necessary to reveal an unanticipated complexity of the YM155 response in neuroblastoma cell lines with acquired drug resistance. Novel findings include that ABCC1 mediates YM155 resistance and that YM155 cross-resistance profiles differ between cell lines adapted to drugs as similar as cisplatin and carboplatin.

[1]  Fengzhi Li,et al.  Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? , 2019, Journal of Experimental & Clinical Cancer Research.

[2]  D. Altieri,et al.  Survivin at a glance , 2019, Journal of Cell Science.

[3]  L. Kaderali,et al.  SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia , 2016, Nature Medicine.

[4]  Mark N. Wass,et al.  Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance , 2016, Cell Death and Disease.

[5]  Joon Sang Lee,et al.  TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma , 2016, Nature Communications.

[6]  M. Michaelis,et al.  ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance , 2016, Oncotarget.

[7]  J. Hagenbuchner,et al.  BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma , 2016, Oncogene.

[8]  S. Dilruba,et al.  Platinum-based drugs: past, present and future , 2016, Cancer Chemotherapy and Pharmacology.

[9]  M. Wass,et al.  Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport , 2016, Oncotarget.

[10]  C. Chen,et al.  AML sensitivity to YM155 is modulated through AKT and Mcl-1. , 2015, Cancer letters.

[11]  C. Mullighan,et al.  YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway , 2015, Journal of Hematology & Oncology.

[12]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[13]  M. Michaelis,et al.  Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status , 2015, Oncotarget.

[14]  M. Haber,et al.  ABC transporters and neuroblastoma. , 2015, Advances in cancer research.

[15]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[16]  B. Klein,et al.  Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1 , 2014, Oncotarget.

[17]  Doris Chen,et al.  The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. , 2014, Nature chemical biology.

[18]  G. Schneider,et al.  Survivin and YM155: how faithful is the liaison? , 2014, Biochimica et biophysica acta.

[19]  F. Westermann,et al.  Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. , 2013, Translational oncology.

[20]  R. Xu,et al.  Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells. , 2013, European review for medical and pharmacological sciences.

[21]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[22]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[23]  S. Baruchel,et al.  Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy , 2013, Journal of pediatric hematology/oncology.

[24]  J. Maris,et al.  Children's Oncology Group's 2013 blueprint for research: Neuroblastoma , 2013, Pediatric blood & cancer.

[25]  C. Cordon-Cardo,et al.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. , 2012, Cancer cell.

[26]  M. Katashima,et al.  Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma , 2012, Investigational New Drugs.

[27]  S. Fulda,et al.  Survivin as a prognostic/predictive marker and molecular target in cancer therapy. , 2012, Current medicinal chemistry.

[28]  A. Palmeira,et al.  Three decades of P-gp inhibitors: skimming through several generations and scaffolds. , 2012, Current medicinal chemistry.

[29]  D. Newton,et al.  The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response , 2012, Cancer Chemotherapy and Pharmacology.

[30]  R. Breitling,et al.  Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents , 2012, Cell Death and Disease.

[31]  G. Giaccone,et al.  A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Versteeg,et al.  Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. , 2012, European journal of cancer.

[33]  I. Ieiri.  Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). , 2012, Drug metabolism and pharmacokinetics.

[34]  R. Breitling,et al.  Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells , 2011, Cell Death and Disease.

[35]  R. Versteeg,et al.  Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. , 2011, Endocrine-related cancer.

[36]  Takashi Usui,et al.  Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein , 2011, Drug Metabolism and Disposition.

[37]  Huanjie Shao,et al.  Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. , 2011, Biochemical pharmacology.

[38]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[39]  M. Sasamata,et al.  Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models , 2011, Cancer science.

[40]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[41]  Yves Pommier,et al.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.

[42]  W. Figg,et al.  Pharmacogenetics of Membrane Transporters: An Update on Current Approaches , 2010, Molecular biotechnology.

[43]  A. Pituch-Noworolska,et al.  Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. , 2010, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[44]  G. Giaccone,et al.  Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Verheul,et al.  Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[46]  M. Fukuoka,et al.  Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[47]  M. Fukuzawa,et al.  Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. , 2009, Journal of pediatric surgery.

[48]  A. Tolcher,et al.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[50]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[51]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[52]  R. Callaghan,et al.  How can we best use structural information on P-glycoprotein to design inhibitors? , 2007, Pharmacology & therapeutics.

[53]  M. Hogarty,et al.  Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. , 2005, Cancer letters.

[54]  A. von Deimling,et al.  Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. , 2005, International journal of oncology.

[55]  C. Monneret,et al.  Etoposide: discovery and medicinal chemistry. , 2004, Current medicinal chemistry.

[56]  R. Blaheta,et al.  Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model , 2003, International journal of cancer.

[57]  S. Binkley,et al.  Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. , 1999, The Journal of pharmacology and experimental therapeutics.

[58]  J. Philippé,et al.  Expression of the MDR1 gene product P‐glycoprotein in childhood neuroblastoma , 1997, Cancer.

[59]  M. Schwab,et al.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. , 1996, Oncogene.

[60]  K. Kohno,et al.  Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. , 1995, British Journal of Cancer.